Drugs in R & D

, Volume 9, Issue 4, pp 251–257 | Cite as

Aminaftone, a Derivative of 4-Aminobenzoic Acid, Downregulates Endothelin-1 Production in ECV304 Cells

An In Vitro Study
  • Raffaella Scorza
  • Alessandro Santaniello
  • Giulia Salazar
  • Stefania Lenna
  • Gualtiero Colombo
  • Flavia Turcatti
  • Lorenzo Beretta
Original Research Article


Background and objective: Endothelin-1 (ET-1) plays a central role in the pathogenesis of several vascular diseases. Aminaftone is a drug used for the treatment of capillary disorders but which has a mechanism of action that is not fully understood. We investigated whether aminaftone may exert its effect by interfering with the production of ET-1.

Methods: Human ECV304 endothelial cells were incubated with interleukin-1β (IL-1β) 100 IU/mL with or without the addition of increasing concentrations of aminaftone (2, 4 or 6 μg/mL). ET-1 concentrations in surnatants were quantified by enzyme immunoassay kit at 3, 6 and 12 hours. Pre-pro-endothelin-1 (PPET-1) gene expressions were also analysed by real-time polymerase chain reaction (RTPCR) at the same time points. Endothelin-converting enzyme (ECE) activity was also determined.

Results: Incubation with IL-1β increased concentrations of ET-1 and PPET-1 relative gene expression. Incubation with aminaftone significantly reduced production of ET-1 in a concentration-dependent manner. A strong direct correlation was found between ET-1 concentrations and PPET-1 relative gene expression, but aminaftone did not influence ECE activity.

Conclusion: Aminaftone inhibits ET-1 production in cell cultures by interfering with transcription of the PPET-1 gene. These findings may account for the clinical efficacy of aminaftone in the treatment of capillary disorders and may encourage conduct of further clinical trials.


ECV304 Cell Chronic Venous Insufficiency Chronic Venous Insufficiency Cellular Sample Minor Groove Binder Probe 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.


  1. 1.
    Villaverde CA, Hernandez R, Santolaya CM. About vascular permeability with aminaftone [in Spanish]. Rev Farmacol Clin Experiment 1989; 6: 9–14Google Scholar
  2. 2.
    Zurlta LE, Colombo M. La fragilità capillare negli ipertesi e nei diabetici: correzione con aminaftone. Acta Gerontol 1982; 32: 172–6Google Scholar
  3. 3.
    Agostini G, Ghittoni S. Clinical contribution to the study of aminaftone in angiological therapy. Folla Angiologica 1973; 21: 209–19Google Scholar
  4. 4.
    Doni A, Mondaini F, Somigli M, et al. Modification of primary hemostasis and capillary fragility induced by aminaftone in inchronic renal insufficiency [in Italian]. Clin Ter 1983; 107: 45–50PubMedGoogle Scholar
  5. 5.
    Smith PD. Update on chronic-venous-insufficiency-induced flammatory processes. Angiology 2001; 52: S35–42PubMedCrossRefGoogle Scholar
  6. 6.
    Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol 1998; 32: S2–13PubMedGoogle Scholar
  7. 7.
    Bergan JJ, Schmid-Schönbein GW, Smith PD, et al. Chronic venous disease. N Engl J Med 2006; 355: 488–98PubMedCrossRefGoogle Scholar
  8. 8.
    La M, Reid JJ. Endothelin-1 and the regulation of vascular tone. Clin Exp Pharmacol Physiol 1995; 22: 315–323PubMedCrossRefGoogle Scholar
  9. 9.
    Suda K, Rothen-Rutishauser B, Gunthert M, et al. Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In Vitro Cell Dev Biol Anim 2001; 37: 505–14PubMedCrossRefGoogle Scholar
  10. 10.
    Orzechowski HD, Richter CM, Funke-Kaiser H, et al. Evidence of alternative promoters directing isoform-specific expression of human endothelin-converting enzyme-1 mRNA in cultured endothelial cells. J Mol Med 1997; 75: 512–21PubMedCrossRefGoogle Scholar
  11. 11.
    Rizza V. Pharmacokinetics and bioavailability of capillarema in 6 human subjects. Pisa: Baldacci, 1988. (Data on file)Google Scholar
  12. 12.
    Peled M, Shaish A, Frishman L, et al. Endothelin B receptor antagonist increases preproendothelin 1 transcription in bovine aortic endothelial cells and in vivo. J Cardiovasc Pharmacol 2006; 47: 668–72PubMedCrossRefGoogle Scholar
  13. 13.
    Grubbs AL, Anstadt MP, Ergul A. Saphenous vein endothelin system expression and activity in African American patients. Arterioscler Thromb Vasc Biol 2002; 22: 1122–7PubMedCrossRefGoogle Scholar
  14. 14.
    Hayasaki-Kajiwara Y, Naya N, Shimamura T, et al. Endothelin generating pathway through endothelin1–31 in human cultured bronchial smooth muscle cells. Br J Pharmacol 1999; 127: 1415–21PubMedCrossRefGoogle Scholar
  15. 15.
    Yoshizumi M, Kurihara H, Morita T, et al. Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells. Biochem Biophys Res Commun 1990; 166: 324–9PubMedCrossRefGoogle Scholar
  16. 16.
    Santaniello A, Salazar G, Lenna S, et al. HLA-B35 upregulates the production of endothelin-1 in HLA-transfected cells: a possible pathogenetic role in pulmonary hypertension. Tissue Antigens 2006; 68: 239–44PubMedCrossRefGoogle Scholar
  17. 17.
    Ozaki S, Ohwaki K, Ihara M, et al. ETB-mediated regulation of extracellular levels of endothelin-1 in cultured human endothelial cells. Biochem Biophys Res Commun 1995; 209: 483–9PubMedCrossRefGoogle Scholar
  18. 18.
    Maemura K, Kurihara H, Morita T, et al. Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology 1992; 38: 29–35PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Raffaella Scorza
    • 1
  • Alessandro Santaniello
    • 1
  • Giulia Salazar
    • 1
  • Stefania Lenna
    • 1
  • Gualtiero Colombo
    • 2
  • Flavia Turcatti
    • 2
  • Lorenzo Beretta
    • 1
  1. 1.Referral Centre for Systemic Autoimmune DiseasesUniversity of Milan and Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina ElenaMilanItaly
  2. 2.Division of Internal MedicineUniversity of Milan and Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina ElenaMilanItaly

Personalised recommendations